Samsung Biologics
27F, 1320-10, Seocho 2-dong, Seocho-gu
Seoul
137-965
Tel: 82-2-2255-8500
Fax: 82-2-2255-8577
Website: http://www.samsungbiologics.com/
104 articles about Samsung Biologics
-
Samsung Biologics Reports 66% Increase in 2020 Revenue Achieving "1 Trillion Won" Target Sales
1/26/2021
Samsung Biologics reported its fourth quarter and full-year 2020 financial results indicating strong business performance, benefitting from increased sales across all plants and significant business agility and operating excellence in overcoming various challenges and global uncertainties amid the COVID-19 pandemic throughout the year.
-
Samsung Biologics Shares 'Vision' for Next Decade at the 39th Annual JP Morgan Healthcare Conference
1/13/2021
Samsung Biologics (207940.KS) set forth its dynamic growth plan for the next decade at the 2021 Annual JP Morgan Healthcare Conference. John Rim , newly appointed President and CEO, unveiled a multidimensional business plan for the company to further expand as a major player in the biopharmaceutical industry, bolstering its
-
On Wednesday, Sage Therapeutics and Samsung Biologics announced that they had found just that in their new chief executive officers.
-
Samsung Biologics drives digital transformation with Plant 4 Virtual Showroom launch
12/4/2020
Samsung Biologics announced the launch of a virtual showroom to provide key features and real-time construction updates of its recently announced Plant 4.
-
Samsung Biologics breaks ground on Super Plant, the world's largest and most innovative bio-manufacturing facility
11/18/2020
Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea.
-
Samsung Biologics announces strategic manufacturing partnership with Lilly to accelerate delivery of COVID-19 antibody treatments
11/17/2020
Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the ultimate goal of making antibody treatments more globally accessible for patients.
-
Samsung Biologics' Virtual Exhibition Hall earns top industry award for digital creativity and innovation
11/4/2020
Samsung Biologics' Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality technology to connect with clients around the world.
-
The life sciences industry is one of the fastest growing in the world. BioSpace provides a rundown of companies announcing facility and job expansions across the U.S. and beyond.
-
Samsung Biologics Establishes Partnership with China Biotech GeneQuantum Healthcare to Collaborate on ADC Development
11/2/2020
Samsung Biologics has entered into a strategic partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate for the treatment of non-small-cell lung carcinoma, triple-negative breast cancer, and other solid tumors.
-
Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab
11/2/2020
Samsung Biologics Co., Ltd. and Checkpoint Therapeutics, Inc., announced the expansion of a long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab.
-
Samsung Biologics' strategic business operations continue to support strong third quarter earnings
10/21/2020
Samsung Biologics maintained steady financial results for its fiscal 2020 third quarter ending September 30, demonstrating confident execution of its ongoing business operations.
-
Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment
10/20/2020
Samsung Biologics has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing.
-
Samsung Biologics partners with BioEleven for cancer immunotherapy development and manufacturing
10/19/2020
Samsung Biologics has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
-
Samsung Biologics and AstraZeneca announced on Monday that they have entered a long-term supply agreement, expected to be valued at approximately $330 million.
-
Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases
9/23/2020
Samsung Biologics (207940.KS) and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.
-
Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply
9/22/2020
Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million . Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca's biologics therapeutic
-
A London AI Hub, a Facility Bigger than the Louvre, Are Among the Newest Footprint Expansions in ...
9/3/2020
GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence. -
Samsung Biologics Posts Strong Second Quarter Earnings With 48.5% Increase In Sales
7/21/2020
Samsung Biologics (KRX: 207940.KS) announced today strong financial results for its fiscal 2020 second quarter ending June 30, 2020 , maintaining steady business performance with a high operating margin at 26.4%. The Company recorded a revenue of KRW 307.7 billion , an increase of 48.5% quarter-on-quarter, and an
-
Samsung Biologics Expands Drug Product Manufacturing Facility in Incheon
7/20/2020
Samsung Biologics (207940.KS) announced a plan to expand its Drug Product (DP) capability in line with increasing market demand and to ensure flexible production capabilities for new and existing clients.
-
Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement
7/15/2020
Samsung Biologics and ImmuneOncia Therapeutics held a signing ceremony for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in 2018.